SYNCOM FORMULATIONS (INDIA) Financial Statement Analysis
|
||
|
The Revenues of SYNCOM FORMULATIONS (INDIA) have increased by 17.45% YoY .
The Earnings Per Share (EPS) of SYNCOM FORMULATIONS (INDIA) has increased by 28.57 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
SYNCOM FORMULATIONS (INDIA) Last 5 Annual Financial Results
[BOM: 524470|NSE : SYNCOMF]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2017 | Mar2016 |
|---|---|---|---|---|---|
| Revenues | ₹263 Cr | ₹224 Cr | ₹220 Cr | ₹185 Cr | ₹184 Cr |
| Expenses | ₹233 Cr | ₹204 Cr | ₹200 Cr | ₹168 Cr | ₹167 Cr |
| Operating Profit (Excl OI) | ₹30 Cr | ₹20 Cr | ₹20 Cr | ₹17 Cr | ₹17 Cr |
| Other Income | ₹14 Cr | ₹15 Cr | ₹12 Cr | ₹2.79 Cr | ₹2.67 Cr |
| Interest | ₹4.72 Cr | ₹3.40 Cr | ₹1.93 Cr | ₹0.33 Cr | ₹0.14 Cr |
| Depreciation | ₹4.72 Cr | ₹4.54 Cr | ₹3.95 Cr | ₹3.12 Cr | ₹3.00 Cr |
| Profit Before Tax | ₹34 Cr | ₹27 Cr | ₹26 Cr | ₹16 Cr | ₹16 Cr |
| Profit After Tax | ₹25 Cr | ₹20 Cr | ₹20 Cr | ₹11 Cr | ₹10 Cr |
| Consolidated Net Profit | ₹25 Cr | ₹20 Cr | ₹20 Cr | ₹11 Cr | ₹10 Cr |
| Earnings Per Share (Rs) | ₹0.27 | ₹0.21 | ₹0.23 | ₹0.13 | ₹0.13 |
| PAT Margin (%) | 9.61 | 8.95 | 9.01 | 5.70 | 5.58 |
| ROE(%) | 9.30 | 8.48 | 11.83 | 9.32 | 9.91 |
| ROCE(%) | 11.05 | 9.68 | 13.72 | 13.28 | 14.72 |
| Total Debt/Equity(x) | 0.25 | 0.32 | 0.27 | 0.11 | 0.05 |
Key Financials |
||
| Market Cap | : | ₹ 1,919.5 Cr |
| Revenue (TTM) | : | ₹ 329.3 Cr |
| Net Profit(TTM) | : | ₹ 33.1 Cr |
| EPS (TTM) | : | ₹ 0.4 |
| P/E (TTM) | : | 57.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SYNCOM FORMULATIONS (INDIA) | 2.8% | -7.4% | 38.2% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.9% | 4.4% | 50% |
| CIPLA | 2.1% | 0.2% | 22.8% |
| DR REDDYS LABORATORIES | -1.1% | 12.1% | 18.1% |
| ZYDUS LIFESCIENCES | 1.8% | 0.9% | 41.3% |
| DIVIS LABORATORIES | 4.6% | -1.1% | 55.6% |
| MANKIND PHARMA | 0.9% | 13.3% | 45.6% |
| TORRENT PHARMACEUTICALS | 1.2% | 2.5% | 48.2% |
| LUPIN | 7.6% | 15.1% | 78.8% |
SYNCOM FORMULATIONS (INDIA) Revenues
[BOM: 524470|NSE : SYNCOMF]
| Y-o-Y | 17.45 % |
| 5 Yr CAGR | 9.40 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹263 Cr | 17.45 | |
| Mar2023 | ₹224 Cr | 2.09 | |
| Mar2022 | ₹220 Cr | 18.85 | |
| Mar2017 | ₹185 Cr | 0.50 | |
| Mar2016 | ₹184 Cr | - | |
SYNCOM FORMULATIONS (INDIA) Operating Profit
[BOM: 524470|NSE : SYNCOMF]
| Y-o-Y | 50.22 % |
| 5 Yr CAGR | 15.72 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹30 Cr | 50.22 | |
| Mar2023 | ₹20 Cr | -0.67 | |
| Mar2022 | ₹20 Cr | 21.04 | |
| Mar2017 | ₹17 Cr | -0.70 | |
| Mar2016 | ₹17 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 27.96 % |
| 5 Yr CAGR | 5.80 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 11.35% | 27.96 | |
| Mar2023 | 8.87% | -2.74 | |
| Mar2022 | 9.12% | 1.79 | |
| Mar2017 | 8.96% | -1.10 | |
| Mar2016 | 9.06% | - | |
SYNCOM FORMULATIONS (INDIA) Profit After Tax
[BOM: 524470|NSE : SYNCOMF]
| Y-o-Y | 26.12 % |
| 5 Yr CAGR | 25.04 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹25 Cr | 26.12 | |
| Mar2023 | ₹20 Cr | 1.42 | |
| Mar2022 | ₹20 Cr | 87.87 | |
| Mar2017 | ₹11 Cr | 1.72 | |
| Mar2016 | ₹10 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 7.37 % |
| 5 Yr CAGR | 14.56 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 9.61 % | 7.37 | |
| Mar2023 | 8.95 % | -0.67 | |
| Mar2022 | 9.01 % | 58.07 | |
| Mar2017 | 5.7 % | 2.15 | |
| Mar2016 | 5.58 % | - | |
SYNCOM FORMULATIONS (INDIA) Earnings Per Share (EPS)
[BOM: 524470|NSE : SYNCOMF]
| Y-o-Y | 28.57 % |
| 5 Yr CAGR | 20.05 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹0.27 | 28.57 | |
| Mar2023 | ₹0.21 | -8.70 | |
| Mar2022 | ₹0.23 | 76.92 | |
| Mar2017 | ₹0.13 | 0.00 | |
| Mar2016 | ₹0.13 | - | |
SYNCOM FORMULATIONS (INDIA) Return on Capital Employed (ROCE)
[BOM: 524470|NSE : SYNCOMF]
| Y-o-Y | 14.15 % |
| 5 Yr CAGR | -6.92 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 11.05% | 14.15 | |
| Mar2023 | 9.68% | -29.45 | |
| Mar2022 | 13.72% | 3.31 | |
| Mar2017 | 13.28% | -9.78 | |
| Mar2016 | 14.72% | - | |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
| Current Share Price | : | ₹20.4 |
| Current MarketCap | : | ₹ 1,919.5 Cr |
| Updated EOD on | : | Jan 02,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SYNCOM FORMULATIONS (INDIA) | 2.8% |
-7.4% |
38.2% |
| SENSEX | 1.9% |
-0.4% |
10.4% |
SYNCOM FORMULATIONS (INDIA) related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 3.1% | 3.3% | 44.8% |
| S&P BSE SMALL CAP | 2.3% | 0.8% | 32.4% |
| S&P BSE MIDSMALLCAP | 1.1% | 1.2% | 30.3% |
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
No NSE index found
You may also like the below Video Courses
FAQ about SYNCOM FORMULATIONS (INDIA) Financials
How the annual revenues of SYNCOM FORMULATIONS (INDIA) have changed ?
The Revenues of SYNCOM FORMULATIONS (INDIA) have increased by 17.45% YoY .
How the Earnings per Share (EPS) of SYNCOM FORMULATIONS (INDIA) have changed?
The Earnings Per Share (EPS) of SYNCOM FORMULATIONS (INDIA) has increased by 28.57 % YoY .
Check out Intrinsic Value of Peers of SYNCOM FORMULATIONS (INDIA)
Compare Stock Analytics of Peers of SYNCOM FORMULATIONS (INDIA)
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
